BGM Group Ltd.
BGM
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $103.5M
$0.27
▼ -16.98%
P/E
—
Mkt Cap
$103.5M
52-Wk Range
$0.23–$11.80
52-Week Range
$0.23 - $11.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 96.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Vertically integrated manufacturing and distribution across APIs and specialty pharmaceuticals
- Established expertise in traditional Chinese medicine derivatives, a growing market segment
- Diversified product portfolio reducing revenue concentration risk across healthcare, agriculture, and food sectors
- Strategic positioning in China's expanding pharmaceutical and agricultural markets
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
No forward estimates available
Increasing global demand for generic APIs and traditional Chinese medicine products
Value
Valuation data unavailable
Momentum
Weak
-14.8% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BGM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $2.1M (+14% YoY). Reported EPS of -$0.00. Gross margin 14.5%.
Reported EPS · last 4Q
Q2 25
-$0.00
Q2 24
$0.01
Revenue trend · last 2Q
—
+14%
Q2 24
Q2 25
$1.9M
$2.1M
Margins · last 2Q
Gross
14.5%
Operating
-15.6%
Profit
-6.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BGM stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related